The management of metastatic bone disease with the combination of bisphosphonates and radiotherapy: From theory to clinical practice

Anti-Cancer Agents in Medicinal Chemistry

Volumn 9, Issue 3, 2009, Pages 326-335

  Vassiliou, V ^a   Kardamakis, D ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

Bisphosphonates; Bone density; Bone metastases; Ibandronate; Pain; Pamidronate; Radiotherapy; Zoledronic acid

Indexed keywords

ANTIPYRETIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; IBANDRONIC ACID; MORPHINE; OPIATE; PAMIDRONIC ACID; SAMARIUM 153; STRONTIUM 85; STRONTIUM 89; ZOLEDRONIC ACID;

ABSENCE OF SIDE EFFECTS; ANALGESIA; ARTHRALGIA; BINDING AFFINITY; BONE DENSITY; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PAIN; CANCER RADIOTHERAPY; CLINICAL TRIAL; DRUG FEVER; DRUG STRUCTURE; FLU LIKE SYNDROME; HUMAN; LUNG TOXICITY; METASTASIS POTENTIAL; MONOTHERAPY; MYALGIA; NONHUMAN; OSSIFICATION; OSTEOLYSIS; PAIN ASSESSMENT; PATHOPHYSIOLOGY; PROSTATE CANCER; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RADIOISOTOPE THERAPY; REVIEW; SINGLE DRUG DOSE; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 65549156063     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871520610909030326     Document Type: Review

References (59)

1. Käkonen, S.M.; Mundy, G.R. Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer, 2003, 97(Suppl 3), 834-839.
2. Brown, H.K.; Healy, J.H. Cancer-principles and practice of oncology; In: De Vita V.T.; Hellman S.; Rosenberg S.A; Eds. 6th ed. Lippincott Williams and Wilkins: Philadelphia, 2001; pp. 2713-2719.
3. Vassiliou, V.; Kalogeropoulou, C.; Christopoulos, C.; Solomou, E.K.; Leotsinides, M.; Kardamakis, D. Combination ibandronate and radiotherapy for the treatment of bone metastases: clinical evaluation and radiologic assessment. Int. J. Radiat. Oncol. Biol. Phys., 2007, 67(1), 264-272.
4. Vassiliou, V.; Kalogeropoulou, C.; Giannopoulou, E.; Leotsinidis, M.; Tsota, I.; Kardamakis, D. A novel study investigating the therapeutic outcome of patients with lytic, mixed and sclerotic bone metastases treated with combined radiotherapy and ibandronate. Clin. Exp. Metastasis, 2007, 24(3), 169-178.
5. Saad, F.; Lipton, A.; Cook, R.; Chen, Y.M.; Smith, M.; Coleman, R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer, 2007, 110(8), 1860-1867.
6. Iddon, J.; Byrne, G.; Bundred, N.J. Bone metastasis in breast cancer: the role of parathyroid hormone related protein. J. Surg. Oncol., 1999, 8(1), 13-25.
7. Kahn, D.; Weiner, G.J.; Ben-Haim, S.; Ponto, L.L.; Madsen, M.T.; Bushnell, D.L.; Watkins, G.L.; Argenyi, E.A.; Hichwa, R.D. Positron emission tomographic measurement of bone marrow blood flow to the pelvis and lumbar vertebrae in young normal adults. Blood, 1994, 83(4), 958-963.
8. Roodman, G.D. Mechanisms of bone metastasis. N. Engl. J. Med., 2004, 350(16), 1655-1664.
9. Susa, M.; Glatt, M.; Teti, A. Tumor bone diseases: Molecular mechanisms and opportunities for novel treatments. Curr. Med. Chem. Anti-Cancer Agents, 2001, 1(3), 313-329.
10. Coleman, R.E. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat. Rev., 2001, 27(3), 165-176.
11. Lipton, A.; Costa, L.; Ali, S.M.; Demers, L.M. Bone markers in the management of metastatic bone disease. Cancer Treat. Rev., 2001, 27(3), 181-185.
12. Vassiliou, V.; Kalogeropoulou, C.; Petsas, T.; Leotsinidis, M.; Kardamakis, D. Clinical and radiological evaluation of patients with lytic, mixed and sclerotic bone metastases from solid tumors: Is there a correlation between the clinical status of patients and the type of bone metastases? Clin. Exp. Metastasis, 2007, 24(1), 49-56.
13. Hoskin, P.J. Scientific and clinical aspects of radiotherapy in the relief of bone pain. Cancer Surv., 1988, 7(1), 69-86.
14. Chow, E.; Harris, K.; Fan, G.; Tsao, M.; Sze, W.M. J. Palliative radiotherapy trials for bone metastases. A systematic review. Clin. Oncol., 2007, 25(11), 1423-1436.
15. Sze, W.M.; Shelley, M.D.; Held, I.; Wilt, T.J.; Mason, M.D. Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy. J. Clin. Oncol., 2003, 15(6), 345-352.
16. Salazar, O.M.; Sandhut, T.; da Motta, M.W.; Escutia, M.; Lanzós-Gonzales, E.; Mouelle-Sone, A.; Moscol, A.;, Zaharia, M.; Zaman, S. Fractionated half-body irradiation (HBI) for the rapid palliation of widespread, symptomatic, metastatic bone disease: a randomized phase III trial of the International Atomic Energy Agency (IAEA). Int. J. Radiat. Oncol. Biol. Phys., 2001, 50(3), 765-775.
17. Finlay, I.G.; Mason, M.D.; Shelley, M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol., 2005, 6(6), 392-400.
18. Fertil, B.; Melaise, E.P. Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: analysis of 101 published survival curves. Int. J. Radiat. Oncol. Biol. Phys., 1985, 11(9), 1699-1707.
19. Hoskin, P.J. Bisphosphonates and radiation therapy for palliation of metastatic bone disease. Cancer Treat. Rev., 2003, 29(4), 321-327.
20. Hoskin P.J.; Ford, H.T.; Harmer, C.L. Hemibody irradiation (HBI) for metastatic bone pain in two histological distinct groups of patients. Clin. Oncol., 1989, 1(2), 67-69.
21. Hoskin, P.J.; Stratford, M.R.L.; Folkes, L.K.; Regan, J.; Yarnold, J.R. Effect of local radiotherapy for bone pain on urinary markers of osteaclast activity. Lancet Oncol., 2000, 355(9213), 1428-1429.
22. Vinholes, J.J.; Purohit, OP.; Abbey, M.E.; Eastell, R.; Coleman, R.E. Relationships between biochemical and symptomatic response in a double-blind randomized trial of pamidronate for metastatic bone disease. Ann. Oncol., 1997, 8(12), 1243-1250.
23. Coleman, R.E. Bisphosphonates: clinical experience. The Oncologist, 2004, 9(Suppl 4), 14-27.
24. Krempien, R.; Niethammer, A.; Harms, W.; Debus, J. Bisphosphonates and bone metastases: current status and future directions. Expert Rev. Anticancer Ther., 2005, 5(2), 295-305.
25. Gridelli, C. The use of bisphosphonates in elderly cancer patients. The Oncologist, 2007, 12(1), 62-71.
26. Aapro, M.; Abrahamsson, P.A.; Body, J.J.; Coleman, R.E.; Costa, L.; Crino, L.; Dirix, L.; Grant, M.; Gralow, J.; Hadji, P.; Hortobagyi, GN.; Jonat, W.; Lipton, A.; Monnier, A.; Paterson, A.H.G.; Rizzoli, R.; Saad, F.; Thürlimann, B. Guidance on the use of bisphosphonates in solid tumors: recommendations of an international expert panel. Ann. Oncol., 2008, 19(3), 420-432.
27. Body, J.J.; Diel, I.J.; Lichinitser; M.R.; Krenser, E.D.; Dornoff, W.; Gordunova, V.A.; Budde, M.; Bergström, B.; MF 4265 Study Group. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann. Oncol., 2003, 14(9), 1399-1405.
28. Body, J.J.; Diel, I.J.; Bell, R.; Pecherstorfer, M.; Lichinitser, M.R.; Lazarev, A.F.; Tripathy, D.; Bergström, B. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain, 2004, 111(3), 306-312.
29. Gralow, J.; Tripathy, D.J. Managing Metastatic bone pain: the role of bisphosphonates. Pain Symptom Manage., 2007, 33(4), 462-472.
30. Pavlakis, N.; Stocker, M. In the Cochrane library: Bisphosphonates for breast cancer; issue 1; Oxford: update software, 2002.
31. Body, J.J.; Diel, I.J.; Lichinitser, M.; Lazarev. A.; Pecherstorfer, M.; Bell, R.; Tripathy, D.; Bergström, B. Br. J. Oral ibandronate reduces the risk of skeletal complications in beast cancer patients with metastatic bone disease: Results from two randomized, placebo-controlled phase III studies. Br. J. Cancer, 2004, 90(6), 1133-1137.
32. Hortobagyi, G.N.; Theriault, R.; Lipton, A.; Porter, L.; Blayney, D.; Sinoff, C.; Wheeler, H.; Simeone, J.F.; Seaman, J.J.; Knight, R.D.; Heffernan, M.; Mellars, K.; Reitsma, D.J. Long term prevention of skeletal complications of metastatic breast cancer with pamidronate. J. Clin. Oncol., 1998, 16(6), 2038-2044.
33. Khono, N.; Aogi, K.; Minami, H.; Nakamura, S.; Asaga, T.; Lino, Y.; Watanabe, T.; Goessl, C.; Ohashi, Y.; Takashima, S. Zole-dronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J. Clin. Oncol., 2005, 23(15), 3314-3321.
34. Rosen, L.; Gordon, D.; Tchekmedyian, S.; Yanagihara, R.; Hirsh, V.; Kizakowski, M.; Pawlicki, M.; de Souza, P.; Zheng, M.; Urbanowitz, G.; Reitsma, D.; Seaman, J.J. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J. Clin. Oncol., 2003, 21(16), 3150-3157.
35. Brown, J.E. Neville-Webbe, H.; Coleman, R.E. The role of bisphosphonates in breast and prostate cancers. Endocr. Relat. Cancer, 2004, 11(2), 207-224.
36. Diel, I.J.; Body, J.J.; Lichinitser, M.R.; Kreuser, E.D.; Dornoff, W.; Gordunova, V.A.; Budde, M.; Bergström, B.; MF 4265 Study Group. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur. J. Cancer, 2004, 40(11), 1704-1712.
37. Diel, I.J. Effectiveness of bisphosphonates on bone pain and quality of life in breast cancer patients with metastatic bone disease: a review. Support. Care Cancer, 2007, 15(11), 1243-1249.
38. Fleisch, H. Development of bisphosphonates. Breast Cancer Res., 2002, 4(1), 30-34.
39. Rogers, M.J.; Gordon, S.; Benford, H.L.; Coxon, F.P.; Luckman, S.P.; Monkkonen, J.; Frith, J.C. Cellular and molecular mechanisms of action of bisphosphonates. Cancer, 2000, 88(Suppl 12), 2961-2978.
40. Green, J.R.; Müller, K.; Jaeggi, K.A. J. Preclinical pharmacology of CGP 42'446, a new, potent, hetero cyclic bisphosphonate compound. Bone Miner. Res., 1994, 9(5), 745-751.
41. Masarachia, P.; Weinreb, M.; Balena, R.; Rodan, G.A. Comparison of the distribution of 3H-aledronate and 3H-etidronate in rat and mouse bones. Bone, 1996, 19(3), 281-290.
42. Sato, M.; Grasser, W.; Endo, N.; Akins, R.; Simmons, H.; Thompson, D.D.; Golub, E.; Rodan, G.A. J. Bisphosphonate action. Aledronate localization in rat bone and effects on osteoclast ultrastructure. Clin. Invest., 1991, 88(6), 2095-2105.
43. Russell, R.G.; Rogers, M.J. Bisphosphonates: from the laboratory to the clinic and back again. Bone, 1999, 25(1), 97-106.
44. Rogers, M.J.; Brown, R.J.; Hodkin, V.; Blackburn, G.M.; Russell, R.G.; Watts, D.J. Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes. Biochem. Biophys. Res. Commun., 1996, 224(3), 863-869.
45. Dunford, J.E.; Thompson, K.; Coxon, F.P.; Luckman, S.P.; Hahn, F.M.; Poulter, C.D.; Ebetino, F.H.; Rogers, M.J. Structure-activity relationships for inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther., 2001, 296(2), 235-242.
46. Gibbs, J.B.; Oliff, A. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annu. Rev. Pharmacol. Toxicol., 1997, 37, 143-166.
47. Hughes, D.E.; Wright, K.R.; Uy, H.L.; Sasaki, A.; Yoneda, T.; Roodman, G.D.; Mundy, G.R.; Boyce, B.F. J. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. Bone Miner. Res., 1995, 10(10), 1478-1487.
48. Steel, G.G. The search for therapeutic gain in the combination of radiotherapy and chemotherapy. Radiother. Oncol., 1988, 11(1), 31-53.
49. Chirgwin, J.M.; Guise, T.A. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit. Rev. Eukaryot. Gene Expr., 2000, 10(2), 159-178.
50. Krempien, R.; Huber, P.E.;, Harms, W.; Treiber, M.; Wannenmacher, M.; Krempien, B. Combination of early bisphosphonate administration and irradiation leads to improved remineralization and restoration of osteolytic bone metastases in an animal model. Cancer, 2003, 98(6),1318-1324.
51. Arrington, S.A.; Damron, T.A.; Mann, K.A.; Allen, M.J. Concurrent administration of zoledronic acid and irradiation leads to improved bone density, biomechanical strength, and microarchitecture in a mouse model of tumor induced osteolysis. J. Surg. Oncol. 2008, 97(3), 284.
52. Quattrocchi, C.C.; Santini, D.; Dell'Aia, P.; Piciucchi, S.; Leoncini, E.; Vincenzi, B.; Grasso, R.F.; Tonini, G.; Zobel, B.B. A prospective analysis of CT density measurements of bone metastases after treatment with zoledronic acid. Skeletal Radiol., 2007, 36(12), 1121-1127.
53. Micke, O.; Berning, D.; Schäefer, U.; Burns, F.; Willich, N. Combination of ibandronate and radiotherapy in metastatic bone disease-results of a randomized study. J. Clin. Oncol., 2003, 22(Suppl), 759.
54. Kouloulias, V.E.; Dardoufas, C.E.; Kouvaris, J.R.; Antypas, C.; Sandilos, P.H.; Matsopoulos, G.K.; Vlahos, L.J. Use of image processing techniques to assess effect of disodium pamidronate in conjunction with radiotherapy in patients with bone metastases. Acta Oncol., 2002, 41(2), 169-174.
55. Kouloulias, E.V.; Kouvaris, R.J.; Antypas, C.; Mystakidou, K.; Matsopoulos, G.; Uzunoglou, N.; Moulopoulos, A.; Vlahos, L.J. An intra-patient dose-escalation study of disodium pamidronate plus radiotherapy versus radiotherapy alone for the treatment of osteolytic metastases. Monitoring of recalcification using image-processing techniques. Strahlenther. Onkol., 2003, 179(7), 471-479.
56. Kouloulias, V.; Matsopoulos, G.; Kouvaris, J.; Dardoufas, C.; Bottomley, A.; Varela, M.; Uzunoglou, N.; Antypas, C.; Metafa, A.; Moulopoulos, A.; Sandilos, P.; Vlahos, L. Radiotherapy in Conjunction with intravenous infusion of 180mg of disodium pamidronate in management of osteolytic metastases from breast cancer: clinical evaluation, biochemical markers, quality of life, and monitoring of recalcification using assessment of grey-level histogram in plain radiographs. Int. J. Radiat. Oncol. Biol. Phys., 2003, 57(1), 143-157.
57. Vassiliou, V.; Vomvas, D.; Christopoulos, C.; Puglisi, M.; Kardamakis, D. Combined radiotherapy-chemotherapy: Lessons from the management of bone metastases or inoperable lung carcinoma. Rev. Clin. Pharmacol. Pharmacokinet Intern. Ed., 2006, 20(2), 120-121.
58. Vassiliou, V.; Kardamakis, D.; Kalogeropoulou, C. Clinical and radiologic response in patients with bone metastases managed with combined radiotherapy and bisphosphonates. J. Surg. Oncol., 2008, 98(7), 567-568.
59. Storto, G.; Klain, M.; Paone, G.; Liuzzi, R.; Molino, L.; Marinelli, A.; Soricelli, A.; Pace, L.; Salvatore, M. Combined therapy Sr 89 and Zoledronic acid in patients with painful bone metastases. Bone, 2006, 39(1), 35-41.